Parkinson's disease drug therapies in the clinical trial pipeline: 2015–2024
5 affiliations
- 1, Sunnyvale, CA, USA
- 2, London, UK
- 3, Pacific Grove, CA, USA
- 4, New York, USA
- 5Parkinson's research advocate, Oxford, UK
Abstract
Background There is an urgent need to find more effective treatments for motor and non-motor symptoms of Parkinson's disease (PD) and to ultimately discover therapies to slow, stop or reverse the condition. Objective To provide an overview of PD drug therapies in Phase 1–3 clinical trials between 2015–2024 in order to highlight research findings and trends, identify opportunities for further research and funding, and provide a common ground for discussion among the patient, research and funding communities. Methods A dataset of PD drug clinical trials registered on ClinicalTrials.gov between 2015–2024 was analyzed and classified by trial focus (symptomatic therapy or disease-modifying therapy), trial phase, therapeutic category and drug novelty. Results The dataset included 444 trials, of which 42% were in Phase 1, 46% in Phase 2 and 12% in Phase 3. 63% of the trials were evaluating symptomatic therapies (ST) and 37% were testing disease-modifying therapies (DMT). 52% of the trials were exploring novel treatments, a third were testing repurposed compounds and the remainder were evaluating reformulations of existing PD drugs. 281 drug interventions were evaluated across the 444 trials. Conclusion The pipeline of clinical trials evaluating PD drug therapies between 2015–2024 contained a diverse set of novel, repurposed and reformulated compounds across a variety of biological pathways. While additional symptomatic treatments received regulatory approval, there are still no treatments to modify the course of the disease.
Related
- Stem cell therapies for chronic obstructive pulmonary disease: mapping the global clinical trial landscape
- Interaction Between Exercise Intensity and Sedentary Behavior on VO2max Change in Patients with De Novo Parkinson Disease: The Study in Parkinson Disease of Exercise (SPARX) Phase 2 Randomized Clinical Trial
- Peripheral Neuropathy in Parkinson’s Disease Treated with Device-Assisted Therapies: How Often It Is Reported Depends on How It Is Sought. A Systematic Review and Meta-Analysis
- Sample Size and Power Calculations Based on Endpoint Responsiveness: Applications to Trials of Disease-Modifying Therapies in Parkinson's Disease
- Therapies for Alcohol Use Disorder in Alcohol-associated Hepatitis Clinical Trials: Integrated Trial Design with a Composite Clinical Outcome as the Primary Endpoint
BibTeX
@article{buff2026parkinsons,
title = {{Parkinson's disease drug therapies in the clinical trial pipeline: 2015–2024}},
author = {Susan Buff and Aleksandra Pilcicka and Kenneth Pitzer and Brian Fiske and Simon RW Stott and Kevin McFarthing},
journal = {Journal of Parkinson’s Disease},
year = {2026},
month = nov,
doi = {10.1177/1877718x261454154},
url = {https://doi.org/10.1177/1877718x261454154},
note = {CC BY},
}
RIS
TY - JOUR
TI - Parkinson's disease drug therapies in the clinical trial pipeline: 2015–2024
AU - Susan Buff
AU - Aleksandra Pilcicka
AU - Kenneth Pitzer
AU - Brian Fiske
AU - Simon RW Stott
AU - Kevin McFarthing
PY - 2026
DA - 2026/11/04
JO - Journal of Parkinson’s Disease
DO - 10.1177/1877718x261454154
UR - https://doi.org/10.1177/1877718x261454154
AB - Background There is an urgent need to find more effective treatments for motor and non-motor symptoms of Parkinson's disease (PD) and to ultimately discover therapies to slow, stop or reverse the condition. Objective To provide an overview of PD drug therapies in Phase 1–3 clinical trials between 2015–2024 in order to highlight research findings and trends, identify opportunities for further research and funding, and provide a common ground for discussion among the patient, research and funding communities. Methods A dataset of PD drug clinical trials registered on ClinicalTrials.gov between 2015–2024 was analyzed and classified by trial focus (symptomatic therapy or disease-modifying therapy), trial phase, therapeutic category and drug novelty. Results The dataset included 444 trials, of which 42% were in Phase 1, 46% in Phase 2 and 12% in Phase 3. 63% of the trials were evaluating symptomatic therapies (ST) and 37% were testing disease-modifying therapies (DMT). 52% of the trials were exploring novel treatments, a third were testing repurposed compounds and the remainder were evaluating reformulations of existing PD drugs. 281 drug interventions were evaluated across the 444 trials. Conclusion The pipeline of clinical trials evaluating PD drug therapies between 2015–2024 contained a diverse set of novel, repurposed and reformulated compounds across a variety of biological pathways. While additional symptomatic treatments received regulatory approval, there are still no treatments to modify the course of the disease.
SN - 1877-7171
SN - 1877-718X
ER -